About Us, Our Customers, Intervention Scope, Business Solutions and Unique Selling Points

About Us, Our Customers, Intervention Scope, Business Solutions and Unique Selling Points Dr. Véronique Foutel Founder & Managing Partner 2016 Value...
Author: Oswald Lewis
4 downloads 1 Views 783KB Size
About Us, Our Customers, Intervention Scope, Business Solutions and Unique Selling Points Dr. Véronique Foutel Founder & Managing Partner

2016

Value Vision Consulting SAS, R.C.S.Paris – SIRET 809 726 615 00010

58 rue du Faubourg Poissonnière F-75010 PARIS, FRANCE +33.(0)1.44.56.94.50, +33 (0)6.13.42.51.65 [email protected] www.valuevisionconsulting.com

About Us Mission

A Management consultancy dedicated to pharmaceuticals • •

• • •

Offering market access oriented services - at pipeline, portfolio, franchise and asset / product level Aimed at detecting, confirming, growing, wrapping, delivering and protecting drug value along the entire value creation chain (from the earliest as possible R&D stage up to several years post launch) Towards all Innovation Ecosystem Stakeholders (1) By de-risking their investment uncertainty and securing rewarding and sustainable market conditions for assets and products By operating on its own or in partnership with French and international seasoned payer field experts depending on the assignments

(1) All key stakeholders successively financing an asset along the entire value chain i.e. the Technology Transfer Offices (TTO), Technology Transfer Acceleration Companies (TTAC), Venture Capitalists (VC), Biotech, Biopharma Industry and ultimately Payers

Dr. Véronique Foutel – Value Vision Consulting Capabilities 

2016

2

About Us Dr Véronique Foutel – Founder & Managing Partner 1984 – 1991 Pharmaceutical Degree - Université de Sciences Pharmaceutiques de Rennes 1991 – 1995 Pharmacy Residency (Assistance Publique Hôpitaux de Paris) - Doctorate in Pharmaceutical Science – Université Paris V (Rapporteur for the Transparency Commitee (AFSSAPS) and assistant of the Public Health Ministry Representative sitting on the French Pricing Commiteee in 1994/1995)

1996 – 2000 Pricing and Health Economics Manager - GlaxoWellcome France and Roche France 2000 – 2003 International Economic Strategy Leader – Strategic Pricing and HE department – F. Hoffmann La Roche Ltd , Basle, Switzerland (late stage products) 2003 – 2004 Pricing & Health Economics Departmental Head - Roche Canada, Toronto 2005 – 2009 Global Strategic Pricing Deputy Head and Head of the Roche Pharma Division, Global Headquarters, Basle, Switzerland (early & late stage portfolio plus licensing-in and out activities, Roche / Chugai Pricing Committee membership) 2009 – 2012 Commercial Contracting Leader for Roche non affiliate – markets , Regional Headquarters, Switzerland, Basle (Balkans, Central Asia, Middle East, Africa, Indian Subcontinent) 2012 – 2013 Managing Director - JNB-Dévelopment / Mapi (a market access consultancy), France, Paris 2013 – 2014 Chief Strategic Marketing Officer - DBV Technologies (biotech), France, Paris 2015

Founder and Managing Partner - VALUE VISION Consulting SAS, France, Paris

A broad professional experience coupled with an excellent payer practices knowledge gained    

Along the entire value chain : As hospital practionner, drug evaluator, payer’s assistant, industry and biotech executive, consultant In both the public (Hospitals, AFSSAPS (today HAS), French Health Ministry) and private sectors (Big pharma, start-up and small-medium size companies) Around the Globe (Europe, North America, Japan, Australia, Emerging markets), By bridging over company functional silos, and by being hands on in many Therapeutic Areas (onco-hematology, immunology, inflammation, metabolism / cardiovascular diseases, virology, CNS (psychiatry and neurodegenerative diseases) Dr. Véronique Foutel – Value Vision Consulting 

2016

3

Our Customers All the Financial Stakeholders Along the Drug Value Creation Chain     

The Technology Transfer Offices (TTO), the Technology Transfer Acceleration Companies (TTAC) Venture Capitalists (VC), Public investors European and Global Headquarters of Biopharma companies Biotech companies French affiliates of international Biopharma Industry, small /medium size pharma enterprises (SME) without a fully-fledged affiliate in France, French distributors of foreign pharma companies  French Payers (through their bidding process for specific topics)

Dr. Véronique Foutel – Value Vision Consulting

2016

4

Our Intervention Scope At Any Stage of the Entire Lifecycle Clients: VC, TTAC, TTO -10 years prior to Launch

Clients : French affiliates/ SME w/o affiliates -36 à -24 months prior to launch to beyond LOE

Clients: HQs / Biotech (International) From -8 years to 18 months prior to launch

Business solutions in Market Access Value identification

Value Development

&

&

Pricing

Pricing assumption

Anchoring

Refinement

POC and PDD

US FDA / EMA MAA

Value Wrapping

Value Protection

&

&

Pricing Policy

Pricing Defence

Loss of Exclusivity

Launch

POC - Proof of Concept/POD- Proof of Developability /MAA - Marketing Authorization Application Dr. Véronique Foutel – Value Vision Consulting

2016

5

Our Business Solutions in Market Access General Access Solutions

Specific Access Solutions

Early stage products

Late stage and in-market products

Access Conditions and Competitive landscape Scanning, Benchmarking, Strategic Access Road Map

Payers & Proxy Payers’ Interviews / Advisory Boards

Asset profiling, Target Product Profile Definition, Value Pillar Identification, Value De-risking Plan, Payer Evidence Set

Payers’ engagements (early dialogues, pricing and reimbursement applications, negotiations)

Pricing Anchoring, Pricing Strategies / Policies, new Pricing Models

Contracting strategies (incl. performance based contracting)

Dr. Véronique Foutel – Value Vision Consulting 

2016

6

Our Business Solutions in Market Access  Can be combined and adapted to customers’ needs, business operations size and configuration, the life cycle stage of products  Are aimed at reconciling value, price, sales and profit and optimizing these four key business determinants  Can be used in many instances like e.g. for :  A strategic positioning definition or revision for a drug asset  A therapeutic indication / therapeutic area trade-off exercise to establish strategic roadmaps for the Research function, or to re-focus some company activities etc…  Patenting purpose  The elaboration or an audit of a commercial strategy and of the related sales potential  A fundraising operation preparation and execution  A licensing-in /-out opportunity assessment  The definition and roll out of a product value proposition  The setting of a drug pricing policy  The preparation and/ or the support of a price negotiation  The re-assessment and / or the defence of in-market products

Dr. Véronique Foutel – Value Vision Consulting 

2016

7

Our Unique Selling Points In isolation, any of the below depicted features can likely be applied to our competitors Our uniqueness comes from the combination of these four unique selling points Profile consultants being exindustrials knowing well both sides

Business Flexibility (mutualization of skills and resources as required by assignments)

Seniority (+ 20 years, knowledge transfer)

Analogue and solution relevance (experience, know-know transfer)

Dr. Véronique Foutel – Value Vision Consulting

2016

8

Looking forward to helping you address your business opportunities and challenges

58 rue du Faubourg Poissonnière F-75010 PARIS, FRANCE T +33.(0)1.44.56.94.50 M +33 (0)6.13.42.51.65 [email protected] www.valuevisionconsulting.com

Dr. Véronique Foutel – Value Vision Consulting

2016

9